Medtronic (NYSE:MDT) is a leading global healthcare solutions company that operates in the medical technology sector. It develops and manufactures medical devices and therapies to address various health conditions. Medtronic competes with other major players in the healthcare industry, such as Johnson & Johnson and Boston Scientific. On January 29, 2026, CICC initiated coverage on Medtronic with a bullish view, assigning it an "Outperform" grade. At the time of this announcement, the stock price was $101.
The stock for Medtronic is currently priced at $101, reflecting a slight increase of 0.21, or 0.21%, from the previous trading session. Today, the stock has fluctuated between a low of $99.69 and a high of $101.59. Over the past year, MDT has reached a high of $106.33 and a low of $79.55. The company, listed on the NYSE, boasts a substantial market capitalization of approximately $129.5 billion. Today's trading volume for MDT stands at 7.67 million shares.
Eaton Vance Worldwide Health Sciences Fund, known for its strategic investments in the health sciences sector, has made a significant move by reducing its stake in Novo Nordisk AS by 49.25%. This decision was revealed in the fund's N-PORT filing for the fourth quarter of 2025. The fund targets companies involved in healthcare product and service innovation, driven by the growth potential associated with aging demographics, innovation, and increasing global incomes.
The fund's strategy focuses on acquiring stocks that are reasonably priced relative to their fundamental value, emphasizing long-term growth potential. This approach aligns with the bullish view on Medtronic, as the company continues to innovate and expand its product offerings in the healthcare sector. The positive outlook from CICC and the strategic moves by Eaton Vance Worldwide Health Sciences Fund highlight the potential for growth and value in the healthcare industry.
